INVESTIGATING TB CO-INFECTION AMONG HIV PATIENTS: PREVALENCE AND ASSOCIATED CLINICAL AND BEHAVIORAL DETERMINANTS
DOI:
https://doi.org/10.71000/hz30ha82Keywords:
HIV, Tuberculosis, , Co-infection, , HIV-TB Prevalence, , Opportunistic Infections, CD4 Count, Antiretroviral Therapy (ART), , Risk FactorsAbstract
Background: The co-existence of Human Immunodeficiency Virus (HIV) and tuberculosis (TB) presents a critical global health challenge, particularly in low- and middle-income countries. TB remains the leading opportunistic infection and primary cause of mortality among individuals living with HIV. Immunosuppression caused by HIV increases susceptibility to TB, while behavioral and structural barriers hinder timely diagnosis, adherence, and care. Addressing this dual epidemic requires a comprehensive understanding of its determinants within vulnerable populations.
Objective: To determine the prevalence of TB among HIV-positive patients and evaluate the demographic, clinical, and behavioral factors contributing to TB co-infection.
Methods: A descriptive cross-sectional study was carried out at General Hospital Lahore over a four-month period. A total of 60 confirmed HIV-positive individuals aged ≥20 years were selected through non-probability convenience sampling. Data collection involved structured questionnaires and review of clinical records, focusing on ART status, CD4 count, viral load, substance use, nutritional status (BMI), TB history, diagnostic method, and healthcare access. Descriptive and inferential statistics were applied, with significance set at p<0.05.
Results: TB prevalence among participants was 83.3% (n=50), with 58.3% (n=35) having extra-pulmonary TB. Only 40% (n=24) completed TB treatment. CD4 counts were <200 cells/mm³ in 45% (n=27), and 58.3% had unsuppressed viral loads. Substance use was reported by 66.7% (n=40), while 41.7% (n=25) were smokers and 48.3% (n=29) consumed alcohol. Mean BMI was 18.4 ± 1.05, and 78.3% (n=47) had difficulty accessing healthcare. Additionally, 75% (n=45) had a household TB contact, and 71.7% (n=43) had other opportunistic infections.
Conclusion: The findings highlight a high burden of HIV-TB co-infection, compounded by behavioral risks, poor treatment adherence, and limited healthcare access. Integrated, patient-centered strategies addressing both medical and social determinants are urgently needed to improve outcomes in this population.
References
UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2022.
WHO. Global tuberculosis report 2022. Geneva: World Health Organization; 2022.
Takarinda KC, et al. Tuberculosis/HIV coinfection treatment failures in Africa: Predictors and implications. Int J Mycobacteriol. 2020;9(4):349-355.
McQuaid CF, et al. The potential impact of COVID-19-related disruption on tuberculosis burden. Eur Respir J. 2020;56(2):2001718.
Patel R, et al. Behavioral factors influencing HIV-TB co-infection: a qualitative study. AIDS Care. 2022;34(5):642-649
Khan M, et al. Immunological factors influencing the prevalence of TB among HIV patients: a review. Clin Infect Dis. 2021;73(2)
Soni S, et al. Socioeconomic factors influencing HIV-TB co-infection in India: a cross-sectional study. BMC Public Health. 2020;20(1):1478.
Turinawe G, Asaasira D, Kajumba MB, Mugumya I, Walusimbi D, Tebagalika FZ, et al. Active tuberculosis disease among people living with HIV on ART who completed tuberculosis preventive therapy at three public hospitals in Uganda. PLoS One. 2024;19(11):e0313284.
Kassaw A, Kefale D, Aytenew TM, Azmeraw M, Agimas MC, Zeleke S, et al. Burden of mortality and its predictors among TB-HIV co-infected patients in Ethiopia: Systematic review and meta-analysis. PLoS One. 2024;19(11):e0312698.
Spinelli MA, Jones BLH, Gandhi M. COVID-19 Outcomes and Risk Factors Among People Living with HIV. Curr HIV/AIDS Rep. 2022;19(5):425-32.
Salnikova A, Makarenko O, Sereda Y, Kiriazova T, Lunze K, DeHovitz J, et al. Depression among people living with tuberculosis and tuberculosis/HIV coinfection in Ukraine: a cross-sectional study. Glob Health Action. 2025;18(1):2448894.
Wondifraw EB, Chanie ES, Gebreeyesus F, Biset G, Tefera BD, Zeleke M. Incidence and predictors of tuberculosis among children on antiretroviral therapy at northeast Ethiopia comprehensive specialized hospitals, 2022; A multicenter retrospective follow-up study. Heliyon. 2022;8(12):e12001.
Zakaria HF, Raru TB, Hassen FA, Ayana GM, Merga BT, Debele GR, et al. Incidence and Predictors of Virological Failure Among Adult HIV/AIDS Patients on Second-Line Anti-Retroviral Therapy, in Selected Public Hospital of Addis Ababa, Ethiopia: Retrospective Follow-Up Study. HIV AIDS (Auckl). 2022;14:319-29.
Wolelaw EH, Hiruy EG, Abdu AM, Mihretie KM. Incidence of death and its predictors among TB/HIV coinfected adult patients receiving anti-retroviral therapy at Gambelia referral hospital, Southwest Ethiopia, 2022. BMC Infect Dis. 2025;25(1):500.
Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, et al. Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort. Eur Respir J. 2023;62(5).
Bizuneh FK, Bizuneh TK, Biwota GT, Abate BB, Ayenew TG. Meta-analysis of TB & HIV co-infection mortality rate in sub-Saharan African children, youth, and adolescents. Ital J Pediatr. 2025;51(1):210.
Gopalakrishnan V, Bose E, Nair U, Cheng Y, Ghebremichael M. Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection. BMC Infect Dis. 2020;20(1):756.
Darge T, Babusha A, Chilo D, Dukessa A, Teferi S. Predictors of severe hepatotoxicity among retroviral infected adults on HAART regimen in Ilubabor Zone, Southwest Ethiopia. Sci Rep. 2024;14(1):8473.
Adhikari N, Bhattarai RB, Basnet R, Joshi LR, Tinkari BS, Thapa A, et al. Prevalence and associated risk factors for tuberculosis among people living with HIV in Nepal. PLoS One. 2022;17(1):e0262720.
Namaganda MM, Mukasa Kafeero H, Nakatumba Nabende J, Kateete DP, Batte C, Wanyengera M, et al. Prevalence and predictors of virological failure among the people living with HIV on antiretroviral treatment in East Africa: evidence from a systematic review with meta-analysis and meta-regression of published studies from 2016 to 2023. HIV Res Clin Pract. 2025;26(1):2490774.
Samizi FG, Panga OD, Mulugu SS, Gitige CG, Mmbaga EJ. Rate and predictors of HIV virological failure among adults on first-line antiretroviral treatment in Dar Es Salaam, Tanzania. J Infect Dev Ctries. 2021;15(6):853-60.
Coorey NJ, Kensitt L, Davies J, Keller E, Sheel M, Chani K, et al. Risk factors for TB in Australia and their association with delayed treatment completion. Int J Tuberc Lung Dis. 2022;26(5):399-405.
Zhandybayeva A, Truzyan N, Shahumyan E, Kulzhabaeva A, Nugmanova Z, Denebayeva A, et al. The survival rate of tuberculosis patients in HIV-treated cohort of 2008-2018 in Almaty, Kazakhstan. J Infect Dev Ctries. 2020;14(11.1):116s-21s.
Frigati LJ, Wilkinson KA, le Roux S, Brown K, Ruzive S, Githinji L, et al. Tuberculosis infection and disease in South African adolescents with perinatally acquired HIV on antiretroviral therapy: a cohort study. J Int AIDS Soc. 2021;24(3):e25671.
Teferi MY, El-Khatib Z, Boltena MT, Andualem AT, Asamoah BO, Biru M, et al. Tuberculosis Treatment Outcome and Predictors in Africa: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2021;18(20).
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rimal Rashid, Nida Feroz, Muhammad Zubair , Muhammad Mudasir Atta , Ramaz Rashid , Manahil Rashid (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
